Full coverage: Pharmaceuticals

The New York-listed pharmaceutical giant is involved with a judicial review of its tax affairs one year after a last-ditch Budget Day stamp duty change added hundreds of millions to the cost of its Allergan acquisition.

So many legal punches have landed on Mallinckrodt that it is facing a knock-out blow at any point. While the disputes engulfing the manufacturer of several controversial drugs unfold in the US, they all link back to the group’s corporate structure and intellectual property vehicles here in Ireland.

The late Tom Lynch was a polymath who played a major role in developing the Irish pharmaceutical industry. Tom Lyons talks to those who he worked with over the decades to understand a fascinating, complex and unique legacy.